Leukemia and Lymphoma

Journal

Publication Venue For

  • Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy 2022
  • Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents 2022
  • Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG 2022
  • Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.  62:1967-1972. 2021
  • Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.  62:2777-2784. 2021
  • Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).  62:368-376. 2021
  • Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.  62:1774-1777. 2021
  • Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.  62:2292-2294. 2021
  • Low-dose vemurafenib monotherapy in BRAFV600E-mutated Erdheim-Chester disease.  61:2733-2737. 2020
  • Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.  61:397-408. 2020
  • Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.  61:3101-3111. 2020
  • RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis.  60:3181-3187. 2019
  • Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.  60:940-946. 2019
  • Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.  60:894-903. 2019
  • The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement.  60:1095-1097. 2019
  • Predictors of survival, treatment patterns, and outcomes in histiocytic sarcoma.  60:553-555. 2019
  • Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey*.  59:2723-2726. 2018
  • Drugging DNA repair to target T-ALL cells..  59:1746-1749. 2018
  • Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.  58:199-203. 2017
  • Estimating the annual volume of hematologic cancer cases per hematologist–oncologist in the United States: are we treating rare cancers too rarely?.  58:251-252. 2017
  • Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.  58:179-184. 2017
  • Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity.  57:2827-2832. 2016
  • Under-recognition of hemophagocytic syndrome in United States’ rural, non-teaching hospitals.  57:2911-2913. 2016
  • Acute promyelocytic leukemia during pregnancy: A systematic analysis of outcome.  57:616-622. 2016
  • Survival of de novo and secondary acute promyelocytic leukemia: A propensity-matched analysis of the SEER database.  57:385-391. 2016
  • Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.  56:3320-3328. 2015
  • Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: Implications for survival and second malignancies.  56:2339-2343. 2015
  • Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.  56:1626-1635. 2015
  • Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.  56:645-649. 2015
  • Prognostic significance of [18F]fluorodeoxyglucose-positron emission tomography in peripheral T-cell lymphoma treated with stem cell transplantation: a retrospective analysis..  56:256-259. 2015
  • Features and outcomes of diffuse large B-cell lymphoma of the thyroid in a large contemporary cohort.  55:283-287. 2014
  • Examining racial differences in diffuse large B-cell lymphoma presentation and survival.  54:268-276. 2013
  • Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients.  53:2444-2448. 2012
  • Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation.  53:2474-2478. 2012
  • Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitro.  53:688-698. 2012
  • Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia.  53:435-440. 2012
  • Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells.  53:315-322. 2012
  • Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: A single institution experience.  51:1251-1259. 2010
  • Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma.  50:781-787. 2009
  • Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.  48:1736-1744. 2007
  • FCRL2 is a Novel Prognostic Marker in B Cell Chronic Lymphocytic Leukemia.  48:S87-S87. 2007
  • The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma.  46:1627-1638. 2005
  • Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.  45:237-245. 2004
  • Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: Results from CALGB study 9013.  44:39-48. 2003
  • CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells.  36:543-558. 2000
  • Matrix metalloproteinases in multiple myeloma.  37:273-281. 2000
  • Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment.  34:35-43. 1999
  • Myeloperoxidase gene expression in infant leukemia: A pediatric oncology group study.  29:145-160. 1998
  • The effect of interferon-α on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia.  28:241-254. 1998
  • Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant.  20:341-345. 1996
  • What is the CLL B-lymphocyte?.  22:13-39. 1996
  • Late intensification therapy in adult acute lymphoid leukemia: Long-term follow-up of the southeastern cancer study group experience.  15:71-78. 1994
  • Pre-b-cell acute lymphoblastic leukemia in childhood.  3:1-6. 1990
  • International Standard Serial Number (issn)

  • 1029-2403
  • 1042-8194
  • Electronic International Standard Serial Number (eissn)

  • 1029-2403